Secondary hypogonadism is a condition where the body produces too little testosterone (or estrogen, in women) because of a problem in the brain, not in the sex organs themselves. Specifically, the hypothalamus or pituitary gland fails to send the right hormonal signals to the testes or ovaries, so they never receive the instruction to produce sex hormones. This distinguishes it from primary hypogonadism, where the gonads themselves are damaged or dysfunctional. Among adult men, the most common form is functional secondary hypogonadism linked to obesity or metabolic disease, and it is often reversible.
How the Hormonal Signal Chain Breaks Down
Reproductive function depends on a communication loop between three structures: the hypothalamus, the pituitary gland, and the gonads. The hypothalamus releases a hormone called GnRH in pulses, which tells the pituitary gland to release two other hormones, LH and FSH. LH stimulates testosterone production in the testes (or estrogen in the ovaries), while FSH supports sperm or egg development. In secondary hypogonadism, this chain breaks at the hypothalamus or pituitary level. The gonads are structurally normal but sit idle because they never get the signal to work.
Several biological mechanisms can disrupt this signaling. High levels of prolactin, for instance, suppress a brain chemical called kisspeptin that normally stimulates GnRH release. Low body fat triggers a similar suppression: when leptin levels drop (as happens with extreme dieting or eating disorders), the brain prioritizes appetite over reproduction by dialing down GnRH output. In breastfeeding women, nerve signals from the nipple trigger a local release of natural opioids in the hypothalamus that suppress GnRH, which is why menstruation often pauses during nursing.
How It Differs From Primary Hypogonadism
The distinction comes down to where the problem originates and what hormone levels look like on a blood test. In primary hypogonadism, the gonads are damaged (from injury, infection, chemotherapy, or a genetic condition like Klinefelter syndrome), so the brain ramps up LH and FSH in an attempt to force them to work harder. The result is low testosterone with high LH and FSH.
In secondary hypogonadism, the brain itself is the bottleneck. Testosterone is low, but LH and FSH are also low or inappropriately normal. This pattern is the key diagnostic clue. If your testosterone is below the normal threshold and your LH and FSH aren’t elevated in response, the problem is almost certainly in the hypothalamus or pituitary rather than in the testes or ovaries.
Common Causes
The causes split into three categories: congenital (present from birth), acquired (from injury or disease later in life), and functional (driven by reversible metabolic factors).
Congenital Causes
The best-known congenital form is Kallmann syndrome, which affects roughly 1 in 10,000 to 1 in 86,000 people depending on the study. It happens because GnRH-producing nerve cells fail to migrate to their correct location in the brain during fetal development. These neurons originate near the olfactory (smell) area of the developing brain, and the same genetic mutations that disrupt their migration also affect smell-processing neurons. This is why people with Kallmann syndrome typically have a diminished or completely absent sense of smell, a feature that sets it apart from other forms of congenital secondary hypogonadism.
Boys born with Kallmann syndrome may have a noticeably small penis or undescended testes. At puberty, affected individuals of either sex fail to develop secondary sex characteristics: no facial hair or voice deepening in males, no breast development or menstruation in females, and no growth spurt in either. Mutations in more than 20 genes have been linked to the condition, though known genetic causes explain only about 30% of cases. Some people also have associated features like a cleft palate, hearing loss, or a missing kidney.
Acquired Causes
Pituitary tumors (particularly prolactin-secreting adenomas) can compress or disrupt the cells that produce LH and FSH. Any mass or lesion that damages the pituitary stalk can also cut off the dopamine signal that normally keeps prolactin in check, leading to elevated prolactin and subsequent GnRH suppression. Traumatic brain injury is likely the most common non-medication-related acquired cause, with an estimated incidence of 6 to 8 cases per 10,000 patient-years. Other acquired causes include pituitary surgery, radiation to the head, iron overload conditions, and infiltrative diseases that damage the hypothalamus or pituitary.
Medications are a major and often underappreciated cause. Opioid pain medications suppress GnRH release directly. Anabolic steroids shut down the brain’s signaling loop through negative feedback: the brain detects high levels of external testosterone and stops producing LH and FSH. Androgen deprivation therapy for prostate cancer is intentionally designed to cause secondary hypogonadism, and its lifetime prevalence may reach 2 to 3% in men between ages 55 and 70.
Functional Causes
The single most common form of secondary hypogonadism in adult men is functional, driven by obesity and metabolic disease. Sometimes called “male obesity secondary hypogonadism,” it involves a multifactorial disruption of the hormonal axis related to excess body fat, insulin resistance, and chronic inflammation. The defining feature of functional hypogonadism is that it reverses when the underlying cause is addressed. Weight loss through diet, exercise, medication, or bariatric surgery consistently restores testosterone levels. Obstructive sleep apnea, which often accompanies obesity, is another contributor that can improve with treatment.
Symptoms
The symptoms depend heavily on when the condition starts. If it begins before puberty (as with Kallmann syndrome), the person simply never enters puberty without treatment. If it develops in adulthood, the symptoms overlap with those of any testosterone deficiency: low libido, erectile dysfunction, fatigue, loss of muscle mass, increased body fat, depressed mood, and difficulty concentrating. Over time, persistently low testosterone leads to reduced bone density, raising the risk of fractures. Women with secondary hypogonadism lose their menstrual periods and may experience hot flashes, vaginal dryness, and reduced fertility.
Because these symptoms are nonspecific and develop gradually, secondary hypogonadism often goes undiagnosed for years. Fatigue and low mood, for example, get attributed to stress or aging before anyone checks hormone levels.
How It’s Diagnosed
Diagnosis requires both symptoms and confirmed low testosterone on blood tests. The Endocrine Society recommends measuring total testosterone on two separate mornings while fasting, because testosterone levels fluctuate throughout the day and peak in the early morning. The generally accepted lower limit of normal for total testosterone is 264 ng/dL. Values consistently below this, especially below 200 ng/dL, strongly suggest hypogonadism.
Once low testosterone is confirmed, measuring LH and FSH distinguishes primary from secondary hypogonadism. Low or normal LH and FSH in the setting of low testosterone points to a secondary cause. Prolactin levels are also checked because elevated prolactin is both a common cause and a clue to a possible pituitary tumor. If prolactin is more than twice the upper limit of normal, a pituitary MRI is strongly recommended since roughly 75% of such cases reveal an adenoma. For men with low LH and low testosterone but normal prolactin, the likelihood of finding a significant pituitary mass on MRI is quite low, and the decision to image depends on individual circumstances.
Treatment Approaches
Treatment depends on two things: the underlying cause and whether the person wants to have children. For functional hypogonadism driven by obesity, addressing the root cause through weight loss is the first-line approach and can fully normalize testosterone without any hormonal treatment.
When a structural or permanent cause is identified and fertility is not a goal, testosterone replacement therapy raises testosterone levels directly. This relieves symptoms effectively but suppresses the body’s remaining LH and FSH production, which shuts down sperm production. For men who want to preserve or restore fertility, the approach is fundamentally different. Instead of replacing testosterone, the goal is to restart the brain-to-gonad signaling chain. Treatment with gonadotropin injections (which mimic LH) can stimulate the testes to produce both testosterone and sperm simultaneously. In men whose hypogonadism developed after puberty, this approach has shown strong results: in one series, all six men treated went from sperm counts below 1 million to above 40 million per ejaculate.
For conditions like Kallmann syndrome, gonadotropin therapy can induce puberty and fertility in many cases, though treatment timelines tend to be longer since the testes have never been fully stimulated before. When a prolactin-secreting pituitary tumor is the cause, treating the tumor (typically with medication that shrinks it) often restores normal hormonal function without the need for ongoing testosterone therapy.